drugset / Trial / NCT00600093

Perioperative Treatment of Parkinsonian Patients With Parenteral Amantadine

NCT00600093

Phase 2 Terminated 20 enrolled Rabin Medical Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether administrating of Amantadine (a dopamine agonist) to patients suffering from Parkinson disease during the perioperative period is safe, and to asses potential benefits of this treatment.

Timeline

Start
2008-01
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Amantadine Unknown 200 mg Intravenous

Indications